MARSH & MCLENNAN COMPANIES, INC. Quarterly Retained Earnings (Accumulated Deficit) in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Marsh & Mclennan Companies, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q1 2010 to Q2 2024.
  • Marsh & Mclennan Companies, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending June 30, 2024 was $24.6B, a 11.8% increase year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $24.6B +$2.6B +11.8% Jun 30, 2024 10-Q 2024-07-18
Q1 2024 $23.5B +$2.51B +12% Mar 31, 2024 10-Q 2024-04-18
Q4 2023 $22.8B +$2.46B +12.1% Dec 31, 2023 10-Q 2024-07-18
Q3 2023 $22B +$2.17B +10.9% Sep 30, 2023 10-Q 2023-10-19
Q2 2023 $22B +$2.1B +10.6% Jun 30, 2023 10-Q 2023-07-20
Q1 2023 $20.9B +$2.03B +10.7% Mar 31, 2023 10-Q 2023-04-20
Q4 2022 $20.3B +$1.91B +10.4% Dec 31, 2022 10-K 2024-02-12
Q3 2022 $19.8B +$2.25B +12.8% Sep 30, 2022 10-Q 2022-10-20
Q2 2022 $19.9B +$2.28B +13% Jun 30, 2022 10-Q 2022-07-21
Q1 2022 $18.9B +$2.14B +12.7% Mar 31, 2022 10-Q 2022-04-21
Q4 2021 $18.4B +$2.12B +13% Dec 31, 2021 10-K 2023-02-13
Q3 2021 $17.6B +$1.69B +10.6% Sep 30, 2021 10-Q 2021-10-21
Q2 2021 $17.6B +$1.54B +9.57% Jun 30, 2021 10-Q 2021-07-22
Q1 2021 $16.8B +$1.29B +8.33% Mar 31, 2021 10-Q 2021-04-27
Q4 2020 $16.3B +$1.07B +7.06% Dec 31, 2020 10-K 2022-02-16
Q3 2020 $15.9B +$1.09B +7.37% Sep 30, 2020 10-Q 2020-10-30
Q2 2020 $16.1B +$1.32B +8.95% Jun 30, 2020 10-Q 2020-07-31
Q1 2020 $15.5B +$848M +5.79% Mar 31, 2020 10-Q 2020-05-01
Q4 2019 $15.2B +$852M +5.94% Dec 31, 2019 10-K 2021-02-17
Q3 2019 $14.8B +$615M +4.33% Sep 30, 2019 10-Q 2019-10-30
Q2 2019 $14.7B +$610M +4.32% Jun 30, 2019 10-Q 2019-08-02
Q1 2019 $14.6B +$830M +6.01% Mar 31, 2019 10-Q 2019-04-26
Q4 2018 $14.3B +$1.21B +9.19% Dec 31, 2018 10-K 2020-02-20
Q3 2018 $14.2B +$1.08B +8.26% Sep 30, 2018 10-Q 2018-10-26
Q2 2018 $14.1B +$1.22B +9.42% Jun 30, 2018 10-Q 2018-07-27
Q1 2018 $13.8B +$1.21B +9.57% Mar 31, 2018 10-Q 2018-04-27
Q4 2017 $13.1B +$752M +6.07% Dec 31, 2017 10-K 2019-02-21
Q3 2017 $13.1B +$1.16B +9.71% Sep 30, 2017 10-Q 2017-10-27
Q2 2017 $12.9B +$1.16B +9.91% Jun 30, 2017 10-Q 2017-07-28
Q1 2017 $12.6B +$1.15B +10% Mar 31, 2017 10-Q 2017-04-28
Q4 2016 $12.4B +$1.09B +9.61% Dec 31, 2016 8-K 2018-05-09
Q3 2016 $12B +$1.03B +9.38% Sep 30, 2016 10-Q 2016-10-28
Q2 2016 $11.8B +$983M +9.13% Jun 30, 2016 10-Q 2016-08-01
Q1 2016 $11.5B +$945M +8.99% Mar 31, 2016 10-Q 2016-05-02
Q4 2015 $11.3B +$967M +9.36% Dec 31, 2015 10-K 2017-02-24
Q3 2015 $10.9B +$886M +8.82% Sep 30, 2015 10-Q 2015-10-29
Q2 2015 $10.8B +$871M +8.8% Jun 30, 2015 10-Q 2015-07-31
Q1 2015 $10.5B +$895M +9.3% Mar 31, 2015 10-Q 2015-05-04
Q4 2014 $10.3B +$883M +9.34% Dec 31, 2014 10-K 2016-02-24
Q3 2014 $10B +$891M +9.74% Sep 30, 2014 10-Q 2014-11-04
Q2 2014 $9.9B +$861M +9.53% Jun 30, 2014 10-Q 2014-08-04
Q1 2014 $9.62B +$834M +9.49% Mar 31, 2014 10-Q 2014-05-08
Q4 2013 $9.45B +$824M +9.55% Dec 31, 2013 10-K 2015-02-26
Q3 2013 $9.15B +$780M +9.32% Sep 30, 2013 10-Q 2013-11-07
Q2 2013 $9.04B +$779M +9.43% Jun 30, 2013 10-Q 2013-08-08
Q1 2013 $8.79B +$733M +9.1% Mar 31, 2013 10-Q 2013-05-09
Q4 2012 $8.63B +$679M +8.54% Dec 31, 2012 10-K 2014-02-27
Q3 2012 $8.37B +$675M +8.77% Sep 30, 2012 10-Q 2012-11-08
Q2 2012 $8.26B +$569M +7.4% Jun 30, 2012 10-Q 2012-08-08
Q1 2012 $8.05B +$525M +6.97% Mar 31, 2012 10-Q 2012-05-08
Q4 2011 $7.95B +$513M +6.9% Dec 31, 2011 8-K 2013-05-10
Q3 2011 $7.7B +$460M +6.36% Sep 30, 2011 10-Q 2011-11-04
Q2 2011 $7.69B +$501M +6.97% Jun 30, 2011 10-Q 2011-08-05
Q1 2011 $7.53B +$466M +6.6% Mar 31, 2011 10-Q 2011-05-06
Q4 2010 $7.44B Dec 31, 2010 10-K 2012-02-28
Q3 2010 $7.24B Sep 30, 2010 10-Q 2010-11-09
Q2 2010 $7.19B Jun 30, 2010 10-Q/A 2010-08-17
Q1 2010 $7.06B Mar 31, 2010 10-Q 2010-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.